Irinotecan
RAS Wild Type
Academic and Community Cancer Research UnitedSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the RAS Wild Type cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Emory University | Phase 3 | BB |
Cetuximab University of Campania Luigi Vanvitelli | Phase 2 | B |
Capecitabine University of Southern California | Phase 3 | B |
Eloxatin University of Southern California | Phase 3 | B |
FLUOROURACILUM University of Southern California | Phase 3 | B |
View all 11 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →